Evaluation of Anticoagulant Activity of Recombinant Hirudin

유전자 재조합에 의해 제조된 하루딘의 항응고 작용

  • 김영식 (서울대학교 천연물과학연구소) ;
  • 엄은미 (서울대학교 천연물과학연구소) ;
  • 정정숙 (덕성여자대학교 약학대학) ;
  • 정춘식 (덕성여자대학교 약학대학) ;
  • 정기화 (덕성여자대학교 약학대학) ;
  • 손정훈 (한국과학기술원 유전공학연구소) ;
  • 최의성 (한국과학기술원 유전공학연구소) ;
  • 이상기 (한국과학기술원 유전공학연구소)
  • Published : 1993.12.01

Abstract

Hirudin is a potent inhibitor of thrombin, which was originally obtained from the medicinal leech (Hirudo medicinalis) Now it is being produced through the recombinant technology on a large scale. Recombinant hirudin has been assayed for the anticoagulant activity by the measurement of clotting time and the inhibition of thrombin actvity using a chromogenic substrate. The assay range of partial thromboplastin time and thrombin time is within $0.2{\sim}1.0 {\mu}g/mι.$ Thrombin time is more sensitive to the measurement of clot. Ex vivo study showed the level of hirudin in rat plasma was highest in 10 min and then it was eliminated slowly. The half-life of r-hirudin was 80~110 min depending on the assay methods. Intraveneous injection of russel viper venom was used for thrombus induction combined with vents cava ligation. Inhibition of venous thrombosis was observed with i.v. hirudin. It was dependent on the concentration of hirudin.

Keywords